Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation to Potentiate Antitumor Immunity
Source abstract
Abstract
The immunosuppressive tumor microenvironment, characterized by impaired antigen presentation, “don’t eat me” signaling, and T-cell exhaustion, challenges effective cancer immunotherapy. Conventional T-cell-redirecting bispecific engagers (BiTEs) show limited efficacy in solid tumors because of poor T-cell infiltration, rapid clearance, and dose-limiting cytokine release associated with the CD3 agonism. Therefore, we aimed to enhance macrophage-mediated tumor clearance and T-cell priming by developing a bispecific macrophage nanoengager (nanoBIME) that integrates dual immune checkpoint blockade (anti-SIRPα and anti-PD-L1) with STING-agonist delivery (SR717) in a single poly(lactic- co -glycolic acid) nanocarrier (BIS-PLGA-NP@SR717). BIS-PLGA-NP@SR717 exhibited uniform nanoscale features, efficient SR717 encapsulation, and stable dual-antibody conjugation, enabling systemic delivery with sustained intracellular release. Dual-ligand presentation markedly enhanced receptor binding and nanoparticle uptake in macrophages and PD-L1-expressing tumor cells. BIS-PLGA-NP@SR717 synergistically promoted macrophage phagocytosis, repolarized tumor-associated macrophages toward an M1 phenotype, enhanced dendritic cell maturation, and CD8 + T-cell activation; additionally, it elevated granzyme B, perforin, and IFN-γ production, resulting in robust T-cell-dependent tumor cell killing. In CT26 tumor-bearing mice, BIS-PLGA-NP@SR717 achieved superior tumor accumulation, deep intratumoral penetration, and dose-dependent tumor regression with minimal systemic toxicity. Transcriptomic profiling further revealed the coordinated activation of phagosome-related pathways, antigen presentation, STING/IFN pathways, chemokine signaling, and T-cell receptor engagement. Collectively, BIS-PLGA-NP@SR717 represents an integrated, multiaxis immunotherapeutic nanoplatform that synchronizes innate activation, macrophage remodeling, and T-cell effector functions. Its modular architecture provides a versatile framework for next-generation immunotherapies for solid tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · interferon and immune responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Precision Medicine, School of Medicine
Sungkyunkwan University
Department of Biomedical Engineering
University of Connecticut
School of Pharmacy
Department of Biopharmaceutical Convergence
College of Pharmacy
Keimyung University
Department of Immunology, School of Medicine
Funding
National Research Foundation of Korea
References (59)
Show source-provided references
1. 10.1038/nrc.2016.3610.1038/nrc.2016.36 ↗
2. 10.1016/j.cell.2018.09.03510.1016/j.cell.2018.09.035 ↗
3. 10.1056/NEJMra170616910.1056/NEJMra1706169 ↗
4. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
5. 10.1016/j.cpt.2022.12.00210.1016/j.cpt.2022.12.002 ↗
6. 10.1038/nature2134910.1038/nature21349 ↗
7. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
8. 10.1016/j.critrevonc.2024.10457710.1016/j.critrevonc.2024.104577 ↗
9. 10.1073/pnas.171087711410.1073/pnas.1710877114 ↗
10. 10.1038/icb.2014.9310.1038/icb.2014.93 ↗
11. 10.1038/s41423-024-01176-410.1038/s41423-024-01176-4 ↗
12. 10.1016/j.jconrel.2024.06.06210.1016/j.jconrel.2024.06.062 ↗
13. 10.1016/j.immuni.2014.06.00810.1016/j.immuni.2014.06.008 ↗
14. 10.1016/j.jconrel.2021.12.02910.1016/j.jconrel.2021.12.029 ↗
15. 10.3389/fonc.2016.0023310.3389/fonc.2016.00233 ↗
16. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
17. 10.1038/nmat377510.1038/nmat3775 ↗
18. 10.1186/s12967-025-06435-010.1186/s12967-025-06435-0 ↗
19. 10.1016/j.jconrel.2023.12.00710.1016/j.jconrel.2023.12.007 ↗
20. 10.1016/j.intimp.2023.11025510.1016/j.intimp.2023.110255 ↗
21. 10.1016/j.cell.2009.05.04610.1016/j.cell.2009.05.046 ↗
22. 10.1016/j.biopha.2024.11620310.1016/j.biopha.2024.116203 ↗
23. 10.1038/s41467-020-18570-x10.1038/s41467-020-18570-x ↗
24. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
25. 10.1002/smtd.20240162310.1002/smtd.202401623 ↗
26. 10.1016/j.phrs.2024.10706310.1016/j.phrs.2024.107063 ↗
27. 10.1021/acscentsci.3c0131010.1021/acscentsci.3c01310 ↗
28. 10.1038/s41467-023-41164-210.1038/s41467-023-41164-2 ↗
29. 10.1096/fj.202403127R10.1096/fj.202403127R ↗
30. 10.1126/science.abb425510.1126/science.abb4255 ↗
31. 10.7150/thno.3757410.7150/thno.37574 ↗
32. 10.1016/j.jconrel.2021.09.03310.1016/j.jconrel.2021.09.033 ↗
33. 10.1016/j.mtbio.2023.10083910.1016/j.mtbio.2023.100839 ↗
34. 10.1016/j.bioactmat.2025.06.03810.1016/j.bioactmat.2025.06.038 ↗
35. 10.1016/j.nantod.2021.10131310.1016/j.nantod.2021.101313 ↗
36. 10.1002/smll.20200424010.1002/smll.202004240 ↗
37. 10.1038/s41467-024-49825-610.1038/s41467-024-49825-6 ↗
38. 10.1038/s41551-020-00675-910.1038/s41551-020-00675-9 ↗
39. 10.1136/jitc-2021-00285210.1136/jitc-2021-002852 ↗
40. 10.1158/1078-0432.CCR-22-223510.1158/1078-0432.CCR-22-2235 ↗
41. 10.1007/s40005-019-00453-z10.1007/s40005-019-00453-z ↗
42. 10.1021/acs.biochem.4c0071210.1021/acs.biochem.4c00712 ↗
43. 10.1016/j.mtbio.2025.10158310.1016/j.mtbio.2025.101583 ↗
44. 10.1126/science.123885610.1126/science.1238856 ↗
45. 10.1038/nature1616910.1038/nature16169 ↗
46. 10.1038/s41586-025-08758-w10.1038/s41586-025-08758-w ↗
47. 10.34133/bmr.028910.34133/bmr.0289 ↗
48. 10.1038/s43018-025-01025-x10.1038/s43018-025-01025-x ↗
49. 10.1016/j.celrep.2018.11.04710.1016/j.celrep.2018.11.047 ↗
50. 10.1126/science.288.5473.205110.1126/science.288.5473.2051 ↗
51. 10.1016/j.celrep.2021.10958710.1016/j.celrep.2021.109587 ↗
52. 10.1186/s40425-019-0772-010.1186/s40425-019-0772-0 ↗
53. 10.1186/s13045-020-00989-w10.1186/s13045-020-00989-w ↗
54. 10.1136/jitc-2021-00405410.1136/jitc-2021-004054 ↗
55. 10.1136/jitc-2022-00656710.1136/jitc-2022-006567 ↗
56. 10.1016/j.colsurfb.2015.04.01510.1016/j.colsurfb.2015.04.015 ↗
57. 10.1186/s40580-021-00274-710.1186/s40580-021-00274-7 ↗
58. 10.1021/acsnano.2c0824010.1021/acsnano.2c08240 ↗
59. 10.1016/j.jim.2019.04.00710.1016/j.jim.2019.04.007 ↗